(Q40211269)

18 September 2017

Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. (English)

1 reference

18 September 2017

1 reference

Rosângela Teixeira

1

1 reference

18 September 2017

Luis A Marcos

series ordinal

2

1 reference

18 September 2017

Scott L Friedman

series ordinal

3

1 reference

18 September 2017

language of work or name

1 reference

22 May 2007

1 reference

18 September 2017

1 reference

18 September 2017

37

1 reference

18 September 2017

8

1 reference

18 September 2017

579-595

1 reference

Hepatocellular carcinoma: overcoming challenges in disease management

18 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatic fibrosis. Pathogenesis and principles of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Antifibrotic agents for liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Treatment of hepatitis C in patients who have decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Updated treatment approach to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Management of hepatitis C virus infection in the setting of liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Treatment of chronic hepatitis C infection in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Matrix metalloproteinases, the pros and cons, in liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Matrix as a modulator of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

The bone marrow functionally contributes to liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatic stellate cell behavior during resolution of liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Detection of Diverse Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes in Peripheral Blood of Infected Persons by Screening for Responses to All Translated Proteins of HCV

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

In Situ Detection of Hepatitis C Virus RNA in Salivary Glands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Recent advances in the molecular biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Mechanisms of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

In search of hepatitis C virus receptor(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatitis C and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Role of Fas ligand in apoptosis induced by hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Insights into the Pathobiology of Hepatitis C Virus-Associated Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

T-cell--mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Analysis of successful immune responses in persons infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Determinants of viral clearance and persistence during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatic T cells and liver tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Natural killer cells: primary target for hepatitis C virus immune evasion strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Natural killer cells inhibit hepatitis C virus expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Fibrosis and disease progression in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Natural killer cells in antiviral defense: function and regulation by innate cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Interferons alpha and beta as immune regulators--a new look

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Ethanol and natural killer cells. I. Activity and immunophenotype in alcoholic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Host genetic factors influence disease progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Host genetic determinants in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Fibrosis in chronic liver diseases: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Noninvasive measures of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Reversal of hepatic fibrosis -- fact or fantasy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Liver fibrosis -- from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Hepatocyte growth factor gene therapy of liver cirrhosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Vascular and cardiac benefits of angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Local cardiac renin-angiotensin system: hypertension and cardiac failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Vascular mediators in the injured liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Role of endothelin in systemic and portal resistance in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

Protease inhibitors suppress TGF-β generation by hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00085.X

10.1111/J.1872-034X.2007.00085.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference